mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism.

mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism.
复制标题

DOI:
10.1371/journal.pone.0026077
复制
发表时间:
2011
期刊:
影响因子:
3.7
通讯作者:
Siegel SJ
Siegel SJ
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Mehta MV;Gandal MJ;Siegel SJ

文献摘要

参考文献

被引文献

相似文献

自闭症谱系障碍(ASD)是一种高度致残性的发育障碍,人口患病率为1-3%。尽管有很强的遗传病因,但目前还没有针对ASD核心症状的治疗选择。新的证据表明,谷氨酸能信号转导功能障碍,特别是通过代谢性谷氨酸受体5(MGluR5)受体,可能导致表型缺陷,并可能成为药物干预的合适靶点。本研究评估了mGluR5受体拮抗剂2-甲基-6-苯乙基-吡啶(MPEP)对丙戊酸(VPA)自闭症小鼠重复和焦虑样行为的治疗潜力。小鼠在出生前13天暴露于VPA中,并在成年后评估重复的自我打扮和大理石埋藏行为。在开阔场地测量焦虑样行为和运动活动。暴露于VPA的小鼠表现出更多的重复和焦虑样行为,这与之前发表的结果一致。在大理石埋藏和自我梳理试验中,MPEP显著减少了VPA处理的小鼠的重复行为,但对运动活动没有影响。这些结果与新兴的临床前文献一致,即mGluR5拮抗剂可能对自闭症的核心症状具有治疗效果。
Autism spectrum disorders (ASD) are highly disabling developmental disorders with a population prevalence of 1–3%. Despite a strong genetic etiology, there are no current therapeutic options that target the core symptoms of ASD. Emerging evidence suggests that dysfunction of glutamatergic signaling, in particular through metabotropic glutamate receptor 5 (mGluR5) receptors, may contribute to phenotypic deficits and may be appropriate targets for pharmacologic intervention. This study assessed the therapeutic potential of 2-methyl-6-phenylethyl-pyrididine (MPEP), an mGluR5-receptor antagonist, on repetitive and anxiety-like behaviors in the valproic acid (VPA) mouse model of autism. Mice were exposed prenatally on day E13 to VPA and assessed for repetitive self-grooming and marble burying behaviors as adults. Anxiety-like behavior and locomotor activity were measured in an open-field. VPA-exposed mice displayed increased repetitive and anxiety-like behaviors, consistent with previously published results. Across both marble burying and self-grooming assays, MPEP significantly reduced repetitive behaviors in VPA-treated mice, but had no effect on locomotor activity. These results are consistent with emerging preclinical literature that mGluR5-antagonists may have therapeutic efficacy for core symptoms of autism.
DOI: 10.1001/archgenpsychiatry.2009.30
发表时间: 2009-06
影响因子: --
作者:
King, Bryan H.;Hollander, Eric;Sikich, Linmarie;McCracken, James T.;Scahill, Lawrence;Bregman, Joel D.;Donnelly, Craig L.;Anagnostou, Evdokia;Dukes, Kimberly;Sullivan, Lisa;Hirtz, Deborah;Wagner, Ann;Ritz, Louise
通讯作者: Ritz, Louise
DOI: 10.1007/s11689-009-9023-x
发表时间: 2009-06
影响因子: 4.9
作者:
Gogolla, Nadine;LeBlanc, Jocelyn J.;Quast, Kathleen B.;Sudhof, Thomas C.;Fagiolini, Michela;Hensch, Takao K.
通讯作者: Hensch, Takao K.
DOI: 10.1016/s0140-6736(09)61376-3
发表时间: 2009-11-07
期刊: LANCET
影响因子: 168.9
作者:
Levy, Susan E.;Mandell, David S.;Schultz, Robert T.
通讯作者: Schultz, Robert T.
DOI: 10.1016/j.neuron.2005.01.038
发表时间: 2005-03-03
期刊: NEURON
影响因子: 16.2
作者:
McBride, SMJ;Choi, CH;Jongens, TA
通讯作者: Jongens, TA
DOI: 10.1016/s0091-3057(02)00828-6
发表时间: 2002-09-01
影响因子: 3.6
作者:
Brodkin, J;Busse, C;Varney, MA
通讯作者: Varney, MA